Omega Healthcare Investors (OHI)
(Delayed Data from NYSE)
$30.78 USD
-0.34 (-1.09%)
Updated May 29, 2024 04:00 PM ET
After-Market: $31.00 +0.22 (0.71%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Omega Healthcare Investors (OHI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$32.79 | $37.00 | $28.00 | 5.37% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Omega Healthcare Investors comes to $32.79. The forecasts range from a low of $28.00 to a high of $37.00. The average price target represents an increase of 5.37% from the last closing price of $31.12.
Analyst Price Targets (14)
Broker Rating
Omega Healthcare Investors currently has an average brokerage recommendation (ABR) of 2.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 2.31 a month ago based on 16 recommendations.
Of the 15 recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 26.67% and 6.67% of all recommendations. A month ago, Strong Buy made up 31.25%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 5 | 5 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 10 | 10 | 10 | 11 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.40 | 2.40 | 2.31 | 2.31 | 2.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/28/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/23/2024 | Wedbush Securities | Richard Anderson | Hold | Hold |
5/6/2024 | JMP Securities | Aaron Hecht | Hold | Hold |
4/1/2024 | Truist Securities | Michael Lewis | Hold | Hold |
3/20/2024 | Scotiabank | Nicholas Yulico | Hold | Hold |
2/19/2024 | BMO Capital Markets | Juan Sanabria | Hold | Hold |
2/8/2024 | Exane BNP Paribas | Nathan D Crossett | Strong Sell | Hold |
1/3/2024 | Mizuho SecuritiesUSA | Vikram Malhotra | Strong Buy | Strong Buy |
1/2/2024 | Robert W. Baird & Co. | Wesley Golladay | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.40 |
ABR (Last week) | 2.40 |
# of Recs in ABR | 15 |
Average Target Price | $32.79 |
LT Growth Rate | 4.70% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 144 of 252 |
Current Quarter EPS Est: | 0.68 |